Tagged: Bevacizumab, Intravitreal
- This topic has 5 replies, 6 voices, and was last updated 7 years, 11 months ago by Chancellor Rogers.
-
AuthorPosts
-
-
January 13, 2017 at 11:30 pm #48679
Mason RussellParticipantI have inquiry regarding Intravitreal preparations using Bevacizumab vials (100mg) which is marketed and approved for IV use only, yet it is being successfully used off label to treat age related macular degeneration.
I need to get feedback from you, especially from pharmacists who have dealt with it regarding requirements and precautions of this preparation.
-
January 14, 2017 at 11:34 pm #48681
Ava GreenParticipant“Various different doses of bevacizumab have been used in the published evidence sources, as well as different dose frequency schedules. The issue of optimal dose and frequency of bevacizumab has still not been conclusively resolved however this submission specifically relates to a standard dose of 1.25 mg of bevacizumab, and this is the dose most commonly used in published studies.” The 1.25 mg dosage is administered monthly.
“Pre-packaged syringes of bevacizumab for intravitreal use are available to purchase from special manufacturing units. Moorfields Pharmaceuticals, of Moorfields NHS hospital, can supply syringes of 1.25 mg in 0.05 ml at £85 per syringe, excluding VAT and delivery charges.
We prepare in BSC of the left over of the CRC regimen including Bevacizumab in the regimen, with the all the precautions.
Regards
-
January 16, 2017 at 6:34 pm #48682
Bartholomew PriceParticipantI am working in Specialist Eye Hospital and ( Bevacizumb) is one of the main anti-VEGF medication with high daily consumption
Yet, it is off labels use for AMD but it has a satisfactory safety profile so far and more cost saving compering to the other approved anti-VEGF
We prepared it in the IV room under standard aseptic techniques at dose 1.25mg/0.5ml is intravitreal injection and at 2.5mg/ml as subconjunctival injectionIf you need more information I will be more than happy to assist
Regards
-
January 17, 2017 at 6:35 am #48683
Candace ButlerParticipantWe used to prepare bevacizumab intravitreal syringes 1.25 mg/0.05 ml in BSC with BUD of 90 days in literature but we used 30 days BUD
-
January 20, 2017 at 8:44 pm #48684
Chancellor EvansParticipantWe batch them in the Sterile Preparation Center, and store them in the Pyxis fridge , which make enhanced the workflow as the medication will be readily available in the unit.
Below are the recipe of each one
BEVACIZUMAB 1.25 MG/0.05 ML INTRAOCULAR
Equipment:
1 mL luer-lock TB syringe Quantity: ~25
Mini-spike Quantity: 1Procedure:
*PRESERVATIVE FREE*
1. Attach a mini-spike to the bevacizumab 25 mg/mL 4 mL vial.
2.Withdraw 0.12 mL of bevacizumab 25 mg/mL into 1 mL syringes to make ~25 syringes.
3. Place luer tip cap on syringe, label and sealStorage: Refrigerate and protect from light
Expiration: 9 daysReferences:
CCHS Recipes
McElhiney, Linda F. Compounding Guide for Ophthalmic Preparations, American Pharmacists Association, 2013
Ophthalmic Drug Facts, 22nd Edition, Wolters Kluwer, Health, Facts & Comparisons, 2011BEVACIZUMAB 2.5 MG/0.1 ML SUBCONJUNCTIVAL
Equipment:
1 mL TB syringe Quantity: 7
Dispensing pin Quantity: 1
10 mL syringe Quantity: 1Procedure:
*PRESERVATIVE FREE*
1. Using a 10 mL syringe withdraw entire contents from bevacizumab 25 mg/mL vial
2. Transfer 0.5 mL of Bevacizumab (25 mg/mL) into 1 mL syringes
3. Repeat until 7 syringes have been pulled
4. Place luer tip cap on syringe, seal and labelStorage: Refrigerate and protect from light
Expiration: 9 daysReferences:
CCHS Recipes
McElhiney, Linda F. Compounding Guide for Ophthalmic Preparations, American Pharmacists Association, 2013
Ophthalmic Drug Facts, 22nd Edition, Wolters Kluwer, Health, Facts & Comparisons, 2011 -
January 22, 2017 at 7:54 pm #48685
Chancellor RogersParticipantThe practice here is to use bevacizumab for intravitreal injection as (1.25mg/0.05ml) injection where we prepared it and dispensed it as a prefilled injection for Retina Clinics
It is prepared under regular aseptic techniques with 2 weeks validity from day of preparation.
As for lidocaine we use the topical gel form and this is regular practice as patient is already receive (Oxybuprocaine Hydrochloride) at assessment which will do the anesthesiaHope I could help
-
-
AuthorPosts
You must be logged in to reply to this topic.